Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia

Journal of Pathology

Volumn 202, Issue 2, 2004, Pages 233-240

  Kang, Gyeong Hoon ^a,c   Lee, Sun ^b   Lee, Hyeon Joo ^a   Hwang, Kyu Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c NONE   (United States)

Author keywords

CpG island; DNA methylation; Prostate; Prostate adenocarcinoma; Prostatic intraepithelial neoplasm; Tumour suppressor gene

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 1142275110     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1503     Document Type: Article

References (37)

1. Feinberg AP, Voelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
2. Rideout WM, Eversole-Cire P, Spruck CH 3rd, et al. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol 1994; 14: 6143-6152.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 71: 141-146.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet 1999; 21: 163-167.
5. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
6. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514-519.
7. McNeal JE, Haillot O, Yemoto C. Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 1995; 27: 258-268.
8. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplifications in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 1997; 10: 1113-1119.
9. Qian J, Bostwick DG, Takahashi S, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 55: 5408-5414.
10. Brooks JD, Weinstein M, Lin X, et al. CpG island methylation changes near the GSTP1 gene in prostate intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998; 7: 531-536.
11. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106: 382-387.
12. Hermans JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-9826.
13. Tsuchiya T, Tamura G, Sato K, et al. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 2000; 19: 3642-3646.
14. Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001; 61: 2399-2403.
15. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999; 93: 4347-4353.
16. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 4515-4518.
17. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B cell lymphoma. J Natl Cancer Inst 2002; 94: 26-32.
18. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000; 60: 129-133.
19. Lo KW, Kwong J, Hui ABU, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-3881.
20. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-1839.
21. Dawson DM, Lawrence EG, McLennan GT, et al. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 1998; 90: 519-523.
22. Heidenreich B, Heidenreich A, Sesterhenn A, Srivastava S, Moul JW, Sesterhenn IA. Aneuploidy of chromosome 9 and the tumour suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000; 38: 475-482.
23. Takayama H, Shin M, Nonomura N, Okuyama A, Aozasa K. p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens from non-transition and transition zones. Jpn J Cancer Res 2000; 91: 941-947.
24. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159: 1815-1826.
25. Nelson WG, De Marzo AM, Beweese TL, et al. Preneoplastic prostate lesion: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001; 952: 135-144.
26. Jerónimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology, 2002; 60: 1131-1135.
27. Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62: 3498-3502.
28. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 1511-1516.
29. Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001; 20: 3528-3532.
30. Usadel H, Brabender J, Danenberg KD, et al. Quantitative APC-promoter methylation analysis in tumor tissues, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 371-375.
31. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61: 8659-8663.
32. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-114.
33. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in localized prostate cancer. A multi-institutional update. J Am Med Assoc 1997; 277: 1445-1450.
34. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124.
35. Guo WH, Weng LQ, Ito K, et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 2002; 21: 8351-8355.
36. Shi H, Maier S, Nimmrich I, et al. Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem 2003; 88: 138-143.
37. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999; 59: 2302-2306.